This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Disease informationAdult Growth Hormone Deficiency (aGHD)Paediatric Growth Hormone Deficiency (pGHD)Small for Gestational Age (SGA)Prader-Willi SyndromeTurner SyndromeChronic Renal InsufficiencySupport & ResourcesVideosMaterials

Click here for Genotropin (somatropin) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Growth failure in Chronic Renal Insufficiency

Chronic renal insufficiency (CRI), which may include end stage renal disease, is defined as a persistent elevation of serum creatinine and/or urea. CRI can be caused by a variety of conditions, including congenital disorders, glomerular disorders and infections1.

Chronic kidney disease (CKD) in children is associated with growth impairment, mainly due to disturbances in growth hormone (GH) metabolism and its main mediator, insulin-like growth factor-I (IGF-I)2.

Growth failure associated with CRI usually begins when the glomerular filtration rate falls to 50% of normal1. However, significant short stature has been seen at all levels of renal function3,4,5.

Causes2
  • Primary causes of CKD in children significantly differ from those that are responsible for the adult onset of the disease
  • The main aetiologic factors of CKD in children are represented by CAKUT (congenital abnormalities of kidney and urinary tract), SRNS (steroid-resistant nephrotic syndrome), chronic glomerulonephritis and renal ciliopathies and for >70% of all paediatric CKD cases when considered together
  • Less common causes include thrombotic microangiopathies (especially atypical haemolytic uraemic syndrome), nephrolithiasis / nephrocalcinosis, Wilms tumour, infectious and interstitial diseases
  • While structural causes clearly predominate in younger patients, the incidence of glomerulonephritis increases in those >12 years old
Clinical presentation4

Children with CRI who have growth impairment exhibit a variety of medical and psychological problems in addition to increased mortality.

Factors contributing to poor growth in children with CKD may include:

  • Young age at onset of CKD
  • Renal tubular disorders (e.g., renal dysplasia)
  • Reduced caloric intake (anorexia, loss of taste, GI dysfunction)
  • Inefficient utilisation of calories
  • Metabolic acidosis
  • Renal osteodystrophy
  • Excessive sodium or water losses
  • Corticosteroids
  • GH–IGF-I resistance

References

NICE Guidance [TA188]. Human growth hormone (somatropin) for the treatment of growth failure in children.Becherucci F, et al. Clinical Kidney Journal 2016, 9: 583–591.Van Dyck M, Bilem N, Proesmans W. Pediatr Nephrol 1999, 13(9): 865–869.Mahan JD, Warady BA. Pediatr Nephrol 2006, 21(7): 917–930.Haffner D, et al. N Engl J Med 2000, 343(13): 923–930.
PP-GEN-GBR-1659. February 2023
Genotropin for paediatric growth hormone disorders

Learn more about the paediatric indications and recommended dosing for Genotropin

Find out moreLoading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​